Skip to content
CYTK·Nasdaq·US

Cytokinetics

Cytokinetics is a biopharmaceutical company that discovers, develops and commercializes muscle activators and muscle inhibitors for diseases in which muscle performance is compromised or declining. Its first commercial product is MYQORZO (aficamten), a cardiac myosin inhibitor the FDA approved in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy. It has transitioned into a fully-integrated specialty biopharmaceutical company, with a specialty cardiology franchise aimed at cardiologists.

Source: SEC 10-K Feb 26, 2026

Recent Activity

Updated Oct 17, 2026
–Cytokinetics announced additional data from the ACACIA-HCM trial, presented at the HFSA Annual Scientific Meeting 2026.
–The additional analyses further characterize exercise performance, treatment effect, dose titration and safety of aficamten in non-obstructive hypertrophic cardiomyopathy (HCM).

Past updates are part of the Pro plan.

Thematic Position

CYTK

Relationship Groups

Partners1
Licensing1
Competitors9

Relationship details are part of the Pro plan.

Ended Relationships

4 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

trade disputeimport restrictions
China-sourced aficamten starting materials exposed to trade disputes and restrictive legislation
SEC 10-KFeb 26, 2026

The full regulatory passage is part of the Pro plan.